In patients with conjunctival melanoma, which involves dysregulation of the MAPK and PI3K/AKT/mTOR pathways, mutations in BRAF, NRAS, and NF1 are commonly observed, while KIT and PTEN mutations occur less frequently [7,8]. This evidence concerns the gene PTEN and malignant conjunctival melanoma.